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Novel three-dimensional bone ‘mapping’
software can help assess progression of
osseous metastases from routine CT
D. Thurtle1,2*, G. M. Treece3, T. Barrett2,4 and V. J. Gnanapragasam1,2
Abstract
Imaging of bone metastasis response to therapy is a research priority. Stradwin is a new software-tool, with demonstrated
sub-voxel accuracy in assessing cortical bone properties from routine CT. We applied this technology to the context of
osseous metastases, with particular focus on disease progression using prostate cancer as a model. 3D–rendered
‘bone-maps’ were produced for 20 men with advanced prostate cancer, including a sub-cohort of 9 who had
undergone serial scans. Correlation between baseline interpretation and assessments of progression between
modalities was assessed. Bone-maps took significantly less time to interpret than CT bone windows (P < 0.001).
Initial bone-mapping, without adjustment, demonstrated sensitivity and specificity for suspicious areas on CT of
70.7% and 73.1% respectively. Evaluating disease over time, concordance between bone-maps and current
practice using RECIST outcomes was 100%.
This study demonstrates the feasibility and potential use of this free post-processing software in the serial assessment
of osseous metastases.
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Introduction
Bone scintigraphy (BS) remains the workhorse for
detection of bone metastases in many cancer types
including prostate cancer (PCa). However, BS has signifi-
cant limitations in assessing changes to osseous metasta-
ses over time, particularly due to ‘flare’ effects and low
specificity [1, 2]. BS also fails to provide any additional
information on soft tissue or nodal metastases. With the
improving efficacy of bone-targeting therapies, such as ra-
dium 223 [3], the evaluation of bone metastasis response
to therapy is of growing importance, and has been made a
Europe-wide research priority [4]. Positron-emission
tomography techniques have shown promise in this set-
ting [4, 5], but remain expensive and often inaccessible
outside of the trial setting. As a result, computed tomog-
raphy (CT) is increasingly used in the serial assessment of
disease over time.
Novel post-processing software developed in Cambridge
(Stradwin) has been demonstrated to accurately assess
bone properties using routine CT. The technique, which
has been described previously, uses a complex model-
based fit approach, calculated from thousands of data-
points across the bone surface assessed by semi-automatic
segmentation [6]. Accurate cortical bone thickness esti-
mates have been demonstrated down to 0.3 mm in cadav-
eric samples and the technique has been validated in vivo
in the context of osteoporosis and hip fracture [6, 7]. Here,
we assessed the feasibility and application of this software
to assess trabecular bone density in osseous metastases,
using PCa as a model. Our particular focus was on the
comparison of disease burden over time.
Materials and methods
Following institutional approval (CUH/ID6669) routine
abdomino-pelvic CT scans of 20 patients with metastatic
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PCa were retrospectively retrieved, anonymised at source,
and processed using Stradwin 5.1 software.1 3-dimensional
rendered ‘bone-maps’ of the pelvis and lower vertebral col-
umn were produced for each patient, with trabecular bone
attenuation coefficients ‘mapped’ to the surface (Additional
file 1). Contemporaneous isotope BS (within 2 months of
CT), were also retrieved. A sub-cohort of 9 men who had
undergone follow-up CT and contemporaneous BS, during
the study period, were selected for further study. The CT
scans of these 9 men were also retrieved and processed.
Bone-maps and the bone-windows of original CT
scans were randomised and reviewed independently by a
consultant radiologist blinded to previous imaging or
clinical information. The radiologist localised suspicious
areas of osseous metastasis using a novel validation tool
(Additional file 1: Figure S1). Time taken to interpret
each modality was recorded. Results for each of the skel-
etal areas isolated on the validation tool were compared
between each modality to calculate comparative sensitiv-
ity and specificity, initially comparing bone-maps to CT.
Data management and analysis was performed in MS
Excel (Washington, USA) and StatsDirect (Altrincham,
UK) respectively.
Comparing baseline and follow-up bone maps, osseous
disease stability, progression or response was assessed
using RECIST outcomes [8]. These outcome decisions
were compared against those made by using the ‘gold
standard’ of current clinical practice, using BS and CT in
combination to assess disease progression or response.
Results
The median (IQR) age across the cohort of 20 men was
73.5 (69.5–76.25) years. Median (IQR) PSA at diagnosis
was 130.5 (26–389) ng/mL. 10 men had a clinical diag-
nosis of PCa. Of the remainder, 5 had histological Grade
Group 5 PCa (Gleason 9 or 10) at diagnosis, 3 had
Grade Group 4 (Gleason 8), and 2 had Grade Group 2
(Gleason 3 + 4). All men had at least one bone metastasis
demonstrated on both BS and the imaged skeleton on CT.
CTs contained a mean (±SD) 281 (±53) images whereas
single 3D–rendered bone-map overviews were produced
for each case (e.g., Fig. 1a). Accordingly, bone-maps took
significantly less time (mean (±SD) 93.6 s (±29.5)) to inter-
pret than CT bone windows (217.3 s (±63.1) (p < 0.001).
Interpretation of bone-maps led to calls of 235 areas
appearing malignant and 47 suspicious, compared to
264 and 28 respectively for CT. Without any software
adjustments, the sensitivity of bone-maps for demon-
strating malignant areas recorded from CT was 70.7%,
with 73.1% specificity. Correlation between CT and BS
interpretation was also assessed, with CT demonstrating
85.6% sensitivity for metastases reported on BS with
64.7% specificity (Table 1).
The median (range) interval between processed CTs in
the sub-cohort assessed for progression was 13 (4–23)
months. The mean (range) time between CT and BS in
this cohort was 4.1 (0–25) days. 7 of these 9 patients
were reported to have progressive disease using CT and
BS in combination, the other 2 had stable disease. Using
bone-maps in isolation the same results were reported,
with the same patients reported to have progressive and
stable disease respectively. This equates to 100%
concordance within our cohort, between bone-maps and
the current clinical standard for assessing disease
progression.
Discussion
Applying software designed for alternative purposes we
have demonstrated proof-of-concept for the use of
Stradwin to non-invasively assess bone metastases. Using
a simple post-processing step, CT data can be trans-
formed in to easily-interpreted single-visualisation 3D–
overviews of osseous disease burden. These single image
bone maps took significantly less time to read, and may
be easier for non-specialists to interpret.
Fig. 1 79-year old male with Grade Group 5 (Gleason 5 + 4) prostate cancer. Anterior (a) and posterior d stills of a 3D bone map with trabecular
bone attenuation coefficients mapped to the surface (legend left of image a). Anterior (c) and posterior (f) isotope bone scans and axial CT
images (b and e) are shown from the same date. Dark blue areas on the bone maps correspond to areas of sclerosis, well-demonstrated in the
left pubis (black arrows a, b, c, d & f) and right acetabulum (white arrows d, e & f). Anterior view of the same patient’s 3D bone map
24 months later (g) demonstrates particular progression in the right ilium (white arrow) and L2 vertebra (black arrow), also demonstrated on the ori-
ginal CT(h) and contemporaneous BS(i)
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The relatively low values for sensitivity and specificity of
bone maps compared to CT should be viewed in the con-
text of only marginally better results when CT was com-
pared to BS. This may be due, in part, to the artificial
situation of viewing the modalities in complete isolation
from one another, though it is also acknowledged an elem-
ent of subjectivity exists with any imaging interpretation.
Without histological correlation we are unable to con-
clude that areas only reported as malignant or suspicious
on bone-maps are indeed false positives, rather this may
reflect inadequacies of our reference modalities.
The technique shows particular promise for compari-
sons of disease over time, with 100% concordance in our
cohort. The potential clinical utility of assessing treat-
ment response is significant given the increasing efficacy
of bone-targeting therapies, inadequacies of BS in this
context, and high costs of functional imaging techniques
such as PET-CT. Although we have focussed here on
assessments of overall disease progression, the technol-
ogy may also be effective in assessing individual bone
metastasis size and response. Evaluating bone metastases
in combination with the software’s validated accuracy in
assessing cortical properties may also be of significant
clinical value in the assessment of pathological fractures.
There are numerous potential advantages to this tech-
nology. CT scans are cheap, quick and widely available;
most patients with cancer will already undergo a baseline
CT scan and as such no additional radiation would be
required. This post-processing software is free-to-use, in-
tuitive and fully compatible with DICOM data. The pro-
duced single-image overviews (e.g., Fig. 1) would be of
value in the multi-disciplinary team meeting or as a
discussion-aide when counselling patients about disease
extent, progression or stability. Bone-maps may also prove
useful adjuncts for radiologists, highlighting areas to par-
ticularly focus upon. This technology would have similar
potential in other cancers that preferentially metastasise
to the bone e.g. breast cancer.
Potential drawbacks include that current processing is
not fully-automated, allowing no standardisation of colour
thresholds between scans, or patients. This processing
step does also require a small amount of additional time.
However, it is anticipated that optimisation of this soft-
ware specifically for use in osseous metastasis could allow
a fully automated, standardised processing protocol. Other
prospective software amendments seek to set thresholds
such that only abnormally sclerotic bone is highlighted,
removing the background ‘noise’ in the final bone maps.
Currently, bone-maps require visual interpretation with
the associated subjectivity herewith. Eventually we antici-
pate that computerised quantification of abnormal areas
from these bone maps may enable estimates of total
skeletal involvement. Such a numerical value would be in-
valuable in assessing disease progression or response to
treatment, and remove the need for visual interpretation
of these 3-dimensional constructs. This could have appli-
cations in therapeutic trial design in addition to routine
clinical practice.
Limitations exist in terms of study design – with a retro-
spective format, lack of a histological gold standard and
limited numbers. It is intuitive that this technique, using
routine non-functional CT, relies upon architectural
changes within the bone. For this reason, when assessing
disease over time against RECIST outcomes it is unlikely
bone maps could demonstrate complete or partial re-
sponse, as burnt-out metastases typically remain sclerotic.
For this reason, functional imaging modalities may be
more sensitive earlier in the metastatic process or when
assessing for early response or non-response to treatment.
In summary we report here a potential quick and cost-
effective method for assessing bone metastasis response.
These promising preliminary results justify further work
on this exciting free technology which we encourage other
institutions to consider trialling as we seek to optimise
and improve its value in this important setting.
Endnotes
1Stradwin is available as a free download from http://
mi.eng.cam.ac.uk/~rwp/stradwin/
Additional file
Additional file 1: Instructional methodology to create 'bone maps'
using Stradwin software and validation tools for skeletal metastases.
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Table 1 Interpretation time, results and sensitivity/specificity for each modality against the reported comparator
Test modality Mean interpretation
time (s)
Malignant areas Suspicious areas Compar-ator Sensitivity
(Exc ‘sus’)
Specificity
(Exc ‘sus’)
Sensitivity
(Inc ‘sus’)
Specificity
(Inc ‘sus’)
Bone Map 96.3 235 47 CT 70.71 73.08 69.05 58.28
CT 222.1 264 28 BS 85.63 64.71 81.56 62.89
These were assessed including or excluding calls of suspicious (‘sus’) areas
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